The biotechnology and pharmaceutical group Novartis has announced plans which would see the company’s production location in Stein in the canton of Aargau opened up for other Life Sciences firms to establish operations there. According to a press release, this would ultimately see the creation of the Rhine Valley Life Sciences Park.
“Switzerland is an important location within our production network”, comments Steffen Lang, Head of Novartis Technical Operations and Group Management member, in the press release. Investments totalling in excess of 200 million Swiss francs in 2020 and 2021 at Novartis locations in both Stein and Schweizerhalle will boost the group’s involvement in the region. “By transforming the Stein location into the Rhine Valley Life Sciences Park, we are sending out a positive signal for Swiss industry and the Aargau region”.
The location is described in the press release as offering an ideal environment, access to highly qualified experts from the region and cutting-edge facilities for the production of cell and gene-based therapies.
The plans drawn up by Novartis have also earned the approval of Aargau Services, the business promotion agency for the canton of Aargau. Annelise Alig Anderhalden, Director of Aargau Services, explains that the whole Sisslerfeld industrial estate represents an important hub for jobs as well as being a focal point of cantonal development plans, while the area additionally boasts huge potential for businesses that offer high added value.